1Dworkin M. Recent advances in the social and developmental biology of the myxobacteria[J]. Microbiol Rev, 1996, 60(1):70- 102. 被引量：1
2Gerth K, Pradella S, Perlova O, et al. Myxobacteria: proficient producers of novel natural products with various biological activities -past and future biotechnological aspects with the focus on the genus Sorangium[J]. J Biotechnol, 2003, 106(2/3) :233 - 253. 被引量：1
4Abraham J, Agrawal M, Bakke S, et al. Phase Ⅰ trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days [ J ]. J Clin Oncol,2003, 21(9): 1866 - 1873. 被引量：1
5Eng C, Kindler HL, Nattam S, et al. A phase Ⅱ trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer[J]. Ann Oncol, 2004, 15(6):928-932. 被引量：1
6Low JA, Wedam SB, Lee JJ, et al. Phase Ⅱ clinical trial of ixabepilone(BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer [J]. J Clin Oncol, 2005, 23(12) :2726 - 2734. 被引量：1
7Wang H, Wang Z, Wang S, et al. Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent[J]. Cancer Chemother Pharmacol, 2005 May 3. [Epub ahead of print] 被引量：1
8Dietzmann A, Kanakis D, Kirches E, et al. Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton[J]. J Neurooncol, 2003, 65(2) :99 - 106. 被引量：1
9Kolman A. Epothilone D (Kosan/Roche) [J]. Curr Opin Investig Drugs, 2004, 5(6):657-667. 被引量：1
10Starks CM, Zhou Y, Liu F, et al. Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations[J]. J Nat Prod, 2003, 66(10):1313- 1317. 被引量：1
10Yamaguchi H,Paranawithana S R,Lee M W,et al.Epo-thilone B analogue(BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells[J].Cancer Research,2002,62:466-471. 被引量：1
